+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Editing Therapeutics Market

  • PDF Icon

    Report

  • 111 Pages
  • August 2024
  • Region: Global
  • BCC Research
  • ID: 4618080

The gene editing therapeutics market is estimated to be $11 million in 2024 and is forecasted to grow at a CAGR of 147% to reach a value of $1 billion by end of 2029.  

Key factors driving market growth include:

  • Increasing prevalence of chronic diseases
  • Increasing prevalence of rare and genetic disorders
  • Increasing strategic initiatives
  • Need for precision medicine

Report Scope

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029.

Also included are company profiles of key players, featuring detailed information regarding each company’s business segments, financials, product portfolios and recent developments.

The Report Includes

  • 15 data tables and 42 additional tables
  • An analysis of the current and future global markets for gene editing therapeutics
  • Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
  • Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region
  • Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies
  • Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and consumer attitudes
  • Competitive intelligence, including companies’ market shares, recent M&A activity, and venture funding
  • Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

Table of Contents

Chapter 1: Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2: Market Overview
  • Genome-Editing Tool Types
  • Meganucleases
  • Zinc Finger Nucleases
  • Transcription Activator-like Effector Nucleases
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
  • Gene editing Therapeutics
Chapter 3: Market Dynamics
  • Market Dynamics Snapshot
  • Market Drivers
    • Increasing Prevalence of Chronic Disease
    • Increasing Prevalence of Rare Genetic Disorders
    • Precision Medicine
    • Increasing Strategic Initiatives
  • Market Restraints
    • Stringent Regulatory Frameworks and Time-Consuming Approval Processes
    • High Cost of Treatment
    • Adverse Events and Long-Term Monitoring
    • Lack of Skilled Workforce
    • Off-Target Impact
  • Market Challenges
    • Patent Disputes
    • Governmental Policies and Regulations
    • Ethical Issues
  • Market Opportunities
Chapter 4: Emerging Technologies and Developments
  • Base Editing
  • Prime Editing
  • Cas-Clover and Cas-FOKl
  • CRISPR Interference and CRISPR Activation
  • RNA Editing
  • Artificial Intelligence in Genome Editing
Chapter 5: Pipeline Analysis
  • Overview
  • Clinical Trial Analysis Based on Technology
  • Clinical Trial Analysis Based on Diseases
  • Designations for Pipeline Drugs
Chapter 6: Patent Analysis
Chapter 7: Market Analysis
  • Casgevy
  • Market Overview
  • Market Analysis
  • Market by Region
  • North America
  • Europe
  • Emerging Markets
Chapter 8: Competitive Intelligence
  • Strategic Initiatives
  • Competitive Landscape
Chapter 9: Sustainability in the Gene Editing Therapeutics Market: Environmental, Social and Governance (ESG) Perspectives
  • ESG Practices in the Gene Editing Companies
  • Concluding Remarks
Chapter 10: Appendix
  • Methodology
  • Sources
  • Acronyms
List of Tables and Figures
Summary Table: Global Market for Gene Editing Therapeutics, Through 2029
Table 1: Comparison of Genome-Editing Tools
Table 2: U.S. Adults Age 50 Years and Older with Multiple Chronic Conditions, 2020-2050
Table 3: Global Cases and Deaths Due to Various Cancers, 2022
Table 4: Gene Editing Index Ratings, 2020
Table 5: Rating Guide
Table 6: Comparison of Cas9-derived Proteins with Regular SpCas9
Table 7: Gene Editing Therapeutic Trials in Phase I, Till May 2024
Table 8: Gene Editing Therapeutic Trials in Phase I/II, II and III, Till May 2024
Table 9: Casgevy Label Expansion Studies, Till May 2024
Table 10: Examples of Some Pipeline Drugs and Their Designations, as of May 2024
Table 11: Patents on CRISPR Therapeutics, Published in 2021
Table 12: Patents on CRISPR Therapeutics, Published in 2022
Table 13: Patents on CRISPR Therapeutics, Published in 2023
Table 14: Global Market for Gene Editing Therapeutics, Through 2029
Table 15: Global Market for Gene Editing Therapeutics, by Region, Through 2029
Table 16: Strategic Initiatives in the Gene Editing Therapeutics Market, 2020-2024
Table 17: Venture Funding for Startups, 2023
Table 18: ESG Initiatives/Practices by Various Gene Editing Companies, 2023
Table 19: ESG Rankings for Companies in the Gene Editing Therapeutics Market, 2023
Table 20: Report Information Sources
Table 21: Glossary of Terms Used in This Report
Table 22: Allogene Therapeutics: Company Snapshot
Table 23: Allogene Therapeutics: Financial Performance, FY 2022 and 2023
Table 24: Allogene Therapeutics: News/Key Developments, 2020-2024
Table 25: Beam Therapeutics: Company Snapshot
Table 26: Beam Therapeutics: Financial Performance, FY 2022 and 2023
Table 27: Beam Therapeutics: News/Key Developments, 2021-2023
Table 28: Caribou Biosciences Inc.: Company Snapshot
Table 29: Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
Table 30: Caribou Biosciences Inc.: News/Key Developments, 2021-2024
Table 31: CRISPR Therapeutics: Company Snapshot
Table 32: CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
Table 33: CRISPR Therapeutics: Product Portfolio
Table 34: CRISPR Therapeutics: News/Key Developments, 2021-2024
Table 35: Editas Medicine: Company Snapshot
Table 36: Editas Medicine: Financial Performance, FY 2022 and 2023
Table 37: Editas Medicine: News/Key Developments, 2022-2024
Table 38: Intellia Therapeutics Inc.: Company Snapshot
Table 39: Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 40: Intellia Therapeutics Inc.: News/Key Developments, 2021-2024
Table 41: Precision Biosciences: Company Snapshot
Table 42: Precision Biosciences: Financial Performance, FY 2022 and 2023
Table 43: Precision Biosciences: News/Key Developments, 2020-2024
Table 44: Sangamo Therapeutics: Company Snapshot
Table 45: Sangamo Therapeutics: Financial Performance, FY 2022 and 2023
Table 46: Sangamo Therapeutics: News/Key Developments, 2024
Table 47: Vertex Pharmaceuticals Inc.: Company Snapshot
Table 48: Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 49: Vertex Pharmaceuticals Inc.: Product Portfolio
Table 50: Vertex Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
Table 51: Verve Therapeutics Inc.: Company Snapshot
Table 52: Verve Therapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 53: Verve Therapeutics Inc.: News/Key Developments, 2019-2024
Table 54: Vor Bio: Company Snapshot
Table 55: Vor Bio: Financial Performance, FY 2022 and 2023
Table 56: Vor Bio: News/Key Developments, 2020-2024List of Figures
Summary Figure: Global Market for Gene Editing Therapeutics, 2021-2029
Figure 1: Genome-Editing Outcomes
Figure 2: Endonucleases Used in Gene Editing Technologies
Figure 3: Advances in Therapeutic Strategies to Treat Life-Threatening Diseases
Figure 4: CRISPR/Cas9 Therapeutics Timeline, Since 1987-Present
Figure 5: CRISPR/Cas9 Therapeutics Delivery Platform
Figure 6: Delivery Method
Figure 7: Market Dynamics of Gene Editing Therapeutics Market
Figure 8: Genetic Disorders
Figure 9: Emerging Technologies in the Genome-Editing Therapeutics Market
Figure 10: Emerging Therapeutics Applications for RNA Editing by Cas Enzymes
Figure 11: Articles on Gene Editing Therapeutics in PubMed, 2004-2024
Figure 12: Share of Clinical Trials on the Genome-Editing Market, by Technology, Through May 2024
Figure 13: Genome-Editing Clinical Trials, by Diseases
Figure 14: Genome-Editing Clinical Trials, by Trial Phase
Figure 15: Genome-Editing Clinical Trials, by Trial Status
Figure 16: Patents Documented, by Top Owners, 2021-2024
Figure 17: Patents Documented, by Type, 2021-2024
Figure 18: Patents Documented, by Type, 2021-2024
Figure 19: Common Strategies Proposed for the Therapeutic Intervention for ß-thalassemia and Sickle Cell Disease
Figure 20: Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 21: Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 22: Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023

Companies Mentioned

  • Allogene Therapeutics
  • Beam Therapeutics
  • Caribou Biosciences Inc.
  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics Inc.
  • Precision Biosciences
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals Inc.
  • Verve Therapeutics Inc.
  • VOR Bio